Alberto Balduzzi

Dr. Alberto Balduzzi

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2023 in Pancreatology
Verified
Journal Article
Closed access
EOEizaburo Ohno
Eizaburo Ohno
ABAlberto Balduzzi
Alberto Balduzzi
Susumu HijiokaSusumu Hijioka
Susumu Hijioka
MPMatteo De Pastena
Matteo De Pastena
GMGiovanni Marchegiani
Giovanni Marchegiani
RSRoberto Salvia
Roberto Salvia

1 September 2021 in Pancreatology
Verified
Journal Article
Closed access
ABAlberto Balduzzi
Alberto Balduzzi
GMGiovanni Marchegiani
Giovanni Marchegiani
TPT. Pollini
T. Pollini
MBM. Biancotto
M. Biancotto
ACA. Caravati
A. Caravati
RSR. Salvia
R. Salvia

1 March 2020 in Pancreatology
Verified
Journal Article
Closed access
ABAlberto Balduzzi
Alberto Balduzzi
GMG. Marchegiani
G. Marchegiani
SAStefano Andrianello
Stefano Andrianello
FRF. Romeo
F. Romeo
AAA. Amodio
A. Amodio
CBC. Bassi
C. Bassi

2 November 2019 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
AEAlessandro Esposito
Alessandro Esposito
ABAlberto Balduzzi
Alberto Balduzzi
MPMatteo De Pastena
Matteo De Pastena
MFMartina Fontana
Martina Fontana
LCLuca Casetti
Luca Casetti
RSRoberto Salvia
Roberto Salvia
Introduction: Minimally invasive surgery (MIS) for pancreatic cancer has become very popular in modern pancreatic surgery. Evidence of the benefits of an MI approach are increasing thanks to prospective studies and randomized controlled studies. Areas covered: Agreement is lacking regarding the oncological feasibility of MIS for pancreatic cancer. Therefore, we performed a systematic review focusing on MIS for cancer of the head, body or tail of the pancreas. A total of 5237 studies were identified. After paper screening, 44 studies (22 on MI-pancreaticoduodenectomy and 22 on MI-distal pancreatectomy) met the eligibility criteria for the present review. The mean morbidity and mortality rates after MIPD were 31% and 4.9%, while overall complication and mortality rates were 32,5% and 1%. Median overall survival after MIPD and MIDP was 21.9 and 29.8 months, respectively. Both surgical and oncological outcomes were comparable to the open approach. Expert opinion: MIS offers advantages to the surgeon thanks to the high definition of the surgical field and the freedom of fine movement of the robot but should be considered only in selected patients and in high volume centers. Further studies are needed to prove the intraoperative and postoperative advantages of MIS compared to open surgery.

3 June 2020 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
RSRoberto Salvia
Roberto Salvia
GMGiovanni Marchegiani
Giovanni Marchegiani
SAStefano Andrianello
Stefano Andrianello
ABAlberto Balduzzi
Alberto Balduzzi
GMGaia Masini
Gaia Masini
CBClaudio Bassi
Claudio Bassi

9 March 2023 in HPB
Verified
Journal Article
Closed access
TPTommaso Pollini
Tommaso Pollini
GMGiovanni Marchegiani
Giovanni Marchegiani
AFAntonio Facciorusso
Antonio Facciorusso
ABAlberto Balduzzi
Alberto Balduzzi
MBMarco Biancotto
Marco Biancotto
RSRoberto Salvia
Roberto Salvia